==== Front Med Gas ResMed Gas ResMGRMedical Gas Research2045-9912Medknow Publications & Media Pvt Ltd India MGR-8-6410.4103/2045-9912.235129ReviewThe role of argon in stroke Li Xiang #Zhang Zhu-Wei #Wang Zhong M.D.*Li Jin-Quan M.D.http://orcid.org/0000-0002-6317-2980*Chen Gang Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China* Correspondence to: Jin-Quan Li, or Zhong Wang, jingquanlisdfyy@163.com. # These authors contributed equally to this work. Author contributions XL and ZWZ were responsible for writing the manuscript. JQL were responsible for its revision. ZW and GC were responsible for its drafting and revision. All authors read and approved the final version of the manuscript for publication. Apr-Jun 2018 03 7 2018 8 2 64 66 Copyright: © 2018 Medical Gas Research2018This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.Stroke, also known as “cerebrovascular accident”, is an acute cerebrovascular disease that is caused by a sudden rupture of blood vessels in the brain or obstruction of the blood supply by blockage of blood vessels, thus including hemorrhagic and ischemic strokes. The incidence of ischemic stroke is higher than that of hemorrhagic stroke, and accounts for 80% of the total number of strokes. However, the mortality rate of hemorrhagic stroke is relatively high. Internal carotid artery and vertebral artery occlusion and stenosis can cause ischemic stroke, and especially males over 40 years of age are at a high risk of morbidity. According to the survey, stroke in urban and rural areas has become the first cause of death in China. It is also the leading cause of disability in Chinese adults. In a word, stroke is characterized by high morbidity, high mortality and high disability rates. Studies have shown that many noble gases have the neuroprotective effects. For example, xenon has been extensively studied in various animal models of neurological injury including stroke, hypoxic-ischemic encephalopathy. Compared to xenon, Argon, as a noble gas, is abundant, cheap and widely applicable, and has been also demonstrated to be neuroprotective in many research studies. In a variety of models, ranging from oxygen-glucose deprivation in cell culture to complex models of mid-cerebral artery occlusion, subarachnoid hemorrhage or retinal ischemia-reperfusion injury in animals. Argon administration after individual injury demonstrated favorable effects, particularly increased cell survival and even improved neuronal function. Therefore the neuroprotective effects of argon may be of possible clinical use for opening a potential therapeutic window in stroke. It is important to illuminate the mechanisms of argon in nerve function and to explore the best use of this gas in stroke treatment. argonstrokeexperimental researchunderlying mechanismclinical researchstroke treatmentneuroprotective effectstherapeutic implications ==== Body INTRODUCTION Stroke is one of the most common causes of death and disability in the world and creates a significant social and economic burden for our society.1 As we know, while stroke could be divided into two types, ischemic and hemorrhagic, the ischemic stroke accounts for approximately 80% of them.23 The majority of ischemic strokes are caused by a large artery occlusion due to thromboembolism.4 Currently, more and more attention has been paid to the role of inert gases such as xenon, helium and argon in the protection of nerve function. All of them possess biological effects that have shown to be neuroprotective in pre-clinical models of ischemic stroke.5 Therefore we can focus on their beneficial effects to solve clinical problems caused by ischemia-induced neuronal death.6 Similar to helium and other noble gases, argon was investigated for its therapeutic properties, as early as in 1930s.5 Argon has a lot of advantages compared to other medical gases. It is more abundant than other noble gases and generates inexpensive costs; what's more, the lack of hypnotic effects in normobaric pressures allows it to become a useful therapeutic agent for many conditions including cerebral ischemia. The effects of argon were tested in different in vitro and in vivo models. Regarding cell-culture based research, injury of neuronal cells by deprivation of glucose and oxygen is a frequently used model, investigating neuroprotective properties of gaseous molecules.7 So, in order to explore the practicability of treatment. we will discuss the impact of argon on stroke injury and the potential mechanisms of neuroprotection on the basis of experimental and clinical studies in this article. EXPERIMENTAL STUDIES OF ARGON IN STROKE As for animal experiments, we have successfully established animal models of hemorrhagic and ischemic stroke, especially ischemic, and applied the gas of argon to treat the subjects after stroke insult. The researchers detect the effects of argon on stroke and explore the potential mechanisms by which this gas can protect the nervous system.8 As everyone knows, animal experiments also belong to basic medical and preclinical research and most of them were aimed to investigate the mechanism of objective gas on neurological status following stroke. Now we find that conclusions of these studies are different to a great extent, and we think this is owing to different experimental conditions and methods. We will analyze several recent experimental studies related to this gas for stroke treatment in this paper (Table 1), and then summarize the outcomes. In the in vitro model of oxygen-glucose deprivation (OGD), it was found that 75% vol/vol argon protected against the cell death of neurons, while however neon and krypton had no effect, and helium exacerbated cell death.9 In a hippocampal organotypic slice subjected to OGD, according to studies, argon (at doses of 25, 50 or 75% vol) was neuroprotective, and this protection could be maintained with a delayed treatment.10 An in vivo transient rat middle cerebral artery occlusion (MCAO) study showed that 50% vol argon administration for 1 hour in ischemia could reduce infarct volume and neurological deficit.11 In brain slices, treatment of argon in different vol (37%, 50% and 75% vol) in post-OGD could produce a reduction in cell death.12 Recently, some studies have shown that in a model of perinatal asphyxia, argon treatment (70% vol) post-hypoxic-ischemic (HI) could reduce infarct volume associated with an increase in the anti-apoptotic protein Bcl-2.13 Table 1 Experimental studies of argon in stroke According to the above experiments, the promising preclinical results of argon applied following ischemia, suggest that argon could be further examined as a potential neuroprotective gas for ischemic stroke in the clinical setting, which we believe it would succeed. MECHANISM OF ARGON IN STROKE The underlying mechanism of the neuroprotective function of argon has not been fully elucidated. However, there is ample evidence to show that argon activates the γ-aminobutyric acid (GABA) receptor by acting at the benzodiazepine binding site,14 and GABA receptor agonists can confer neuroprotection after ischemia via the phosphoinositide 3-kinase pathway15 or by abating the phosphorylation of the NR2A subunit of the N-methyl D-aspartic acid (NMDA) receptor.16 Here we will discuss both pathways of how argon protects neurons. Firstly, as we all know, the survival or death of neurons is determined by the balance between pro-survival and pro-apoptosis signals. The Akt (protein kinase B) serine/threonine kinases, as the downstream of phosphatidylinositol 3-kinase (PI-3K), are important mediators of cell survival in brain ischemia. The c-Jun N-terminal kinase (JNK) pathways are stress-activated mitogen-activated protein kinase modules which can be stimulated by brain ischemia. Therefore, one of the mechanisms of cell survival may be the inhibition of the activity of stress-activated kinase cascades. A lot of pro-apoptotic proteins have already been identified as direct Akt substrates, including glycogen synthase kinase 3 (GSK-3), BAD, caspase-9, and apoptosis signal-regulating kinase 1 (ASK1), which were suppressed upon phosphorylation by Akt.17181920 Specifically, by increasing Akt activity, the suppression of the ASK1-mitogen-activated extracellular signal-regulated kinase (MEK)-JNK pathways dependent on phosphorylation of serine 83 of ASK1 would be activated,2021 otherwise ASK1 would phosphorylate and activate mitogen-activated protein kinase kinase 4 (MKK4) or MKK7 which in turn induce JNK kinase activities.15 So we believe that argon can exerted neuroprotective effect via PI-3K/Akt pathway, which could inhibit the ASK1-JNK cascade, by activating the GABA receptor. Secondly, glutamate, as a major excitatory neurotransmitter in the central nervous system (CNS), is frequently researched because it is related to the development of cerebral ischemia induced cell death. Glutamate receptors are mainly classified into two groups: metabotropic glutamate receptors (mGluRs) and ionotropic glutamate receptors (iGluRs). The ionotropic glutamate receptors have been divided into three classes pharmacologically: NMDA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate (KA) receptors. The NMDA receptor acts as a ligand-gated calcium channel, which plays an important role in neuronal development, addiction, learning and memory.22 Over-excessive release of glutamate will cause over-activation of glutamate receptors, mainly NMDA-type, and subsequent calcium overload, all known as excitotoxicity, and then will activate calcium-dependent signaling cascade reactions of postsynaptic neurons that eventually leads to neuronal death.23 According to the study by other researchers, the NMDA receptors are formed by two classes of subunits, a principal NR1 subunit and modulatory NR2 subunits (NR2A–NR2D).24 NMDA receptors are phosphorylated on tyrosine residues of NR2 subunits, especially NR2A and NR2B.25 The protective effect of nerve function is mediated by argon through intervening in the above two pathways (Figure 1). Figure 1 The potential mechanisms of the inert gas on protecting neuron system after ischemia. Note: Argon activates the γ-aminobutyric acid (GABA) receptor by acting at the benzodiazepine binding site and GABA receptor agonists can come into being neuroprotection after ischemia via the phosphoinositide 3-kinase (PI-3K)/Akt(protein kinase B) pathway or by abating the phosphorylation of the NR2A subunit of the N-methyl D-aspartic acid (NMDA) receptor. ASK-1: Apoptosis signal-regulating kinase 1; MKK: mitogen-activated protein kinase kinase; TNK: tenecteplase. CLINICAL STUDIES AND POSSIBLE THERAPEUTIC IMPLICATIONS OF ARGON IN STROKE A decade of investigation on the effects of xenon has led to a clinical trial that may yet change clinical care of perinatal asphyxia. The findings of Loetscher and his colleagues should encourage the pursuit of argon as a neuroprotective alternative/supplement to xenon.26 The potential value for the clinical application of argon needs to be further explored through tests of clinical safety and translational research. According to the data of the current research, there is an increasing amount of evidence that at the vol of 50-70% argon may have potentially neuroprotective and therapeutic properties and be beneficial for preventing brain injury, by protecting neurons in the brain through above two pathways. Although there is insufficient clinical evidence that argon can effectively treat stroke. Future studies should focus on clinical experiments to further explore the use method, dosage and adverse reactions of argon gas. We believe that the argon will open up a new method to protect nervous system. Additional files Open peer review reports 1, 2. Open peer review report 1 Click here for additional data file. Open peer review report 2 Click here for additional data file. Conflicts of interest The authors declare that they have no competing interests. Financial support None. Copyright license agreement The Copyright License Agreement has been signed by all authors before publication. Plagiarism check Checked twice by iThenticate. Peer review Externally peer reviewed. Open peer reviewers Qin Hu, Shanghai Jiao Tong University School of Medicine, China; Robert Ostrowski, Polish Academy of Sciences Medical Research Centre, Poland. ==== Refs REFERENCES 1 Sosin DM Sniezek JE Thurman DJ Incidence of mild and moderate brain injury in the United States, 1991 Brain Inj 1996 10 47 54 8680392 2 Moustafa RR Baron JC Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery Br J Pharmacol 2008 153 Suppl 1 S44 54 18037922 3 Chopp M Li Y Treatment of stroke and intracerebral hemorrhage with cellular and pharmacological restorative therapies Acta Neurochir Suppl 2008 105 79 83 19066087 4 Grysiewicz RA Thomas K Pandey DK Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors Neurol Clin 2008 26 871 895, vii 19026895 5 Sutherland BA Harrison JC Nair SM Sammut IA Inhalation gases or gaseous mediators as neuroprotectants for cerebral ischaemia Curr Drug Targets 2013 14 56 73 23170797 6 Abraini JH David HN Lemaire M Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon Ann N Y Acad Sci 2005 1053 289 300 16179534 7 Ulbrich F Goebel U The molecular pathway of argon-mediated neuroprotection Int J Mol Sci 2016 17 E1816 27809248 8 Deng J Lei C Chen Y Neuroprotective gases--fantasy or reality for clinical use? Prog Neurobiol 2014 115 210 245 24440817 9 Jawad N Rizvi M Gu J Neuroprotection (and lack of neuroprotection) afforded by a series of noble gases in an in vitro model of neuronal injury Neurosci Lett 2009 460 232 236 19500647 10 Loetscher PD Rossaint J Rossaint R Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury Crit Care 2009 13 R206 20017934 11 Ryang YM Fahlenkamp AV Rossaint R Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats Crit Care Med 2011 39 1448 1453 21336110 12 David HN Haelewyn B Degoulet M Colomb DG Jr Risso JJ Abraini JH Ex vivo and in vivo neuroprotection induced by argon when given after an excitotoxic or ischemic insult PLoS One 2012 7 e30934 22383981 13 Zhuang L Yang T Zhao H The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats Crit Care Med 2012 40 1724 1730 22610177 14 Abraini JH Kriem B Balon N Rostain JC Risso JJ Gamma-aminobutyric acid neuropharmacological investigations on narcosis produced by nitrogen, argon, or nitrous oxide Anesth Analg 2003 96 746 749 table of contents 12598256 15 Xu J Li C Yin XH Zhang GY Additive neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade Neuropharmacology 2008 54 1029 1040 18410948 16 Zhang F Li C Wang R Activation of GABA receptors attenuates neuronal apoptosis through inhibiting the tyrosine phosphorylation of NR2A by Src after cerebral ischemia and reperfusion Neuroscience 2007 150 938 949 18022328 17 Cardone MH Roy N Stennicke HR Regulation of cell death protease caspase-9 by phosphorylation Science 1998 282 1318 1321 9812896 18 Cross DA Alessi DR Cohen P Andjelkovich M Hemmings BA Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature 1995 378 785 789 8524413 19 Datta SR Dudek H Tao X Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 1997 91 231 241 9346240 20 Kim AH Khursigara G Sun X Franke TF Chao MV Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1 Mol Cell Biol 2001 21 893 901 11154276 21 Yoon SO Kim MM Park SJ Kim D Chung J Chung AS Selenite suppresses hydrogen peroxide-induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3-K/Akt pathways FASEB J 2002 16 111 113 11709494 22 Kumari M Ticku MK Regulation of NMDA receptors by ethanol Prog Drug Res 2000 54 152 189 10857388 23 Lee JM Zipfel GJ Choi DW The changing landscape of ischaemic brain injury mechanisms Nature 1999 399 A7 14 10392575 24 Kutsuwada T Kashiwabuchi N Mori H Molecular diversity of the NMDA receptor channel Nature 1992 358 36 41 1377365 25 Lau LF Huganir RL Differential tyrosine phosphorylation of N-methyl-D-aspartate receptor subunits J Biol Chem 1995 270 20036 20041 7544350 26 DSanders RD Ma D Maze M Argon neuroprotection Crit Care 2010 14 117 20236500